Parkinson’s disease (PD) is the second most common neurodegenerative disease, affecting more than ten million people worldwide. There are 60,000 people newly diagnosed every year.

Even with the current standard of care therapy, patients can eventually develop debilitating motor complications. The economic burden of disease is estimated to be over $51 billion annually (MJFF, 2019)

iStock 1097802216 technology

Currently, there are no disease-modifying agents available to patients.

brain striatum sn overview


Around 50% of dopamine neurons in the substantia nigra are lost before a PD diagnosis. Cell replacement therapy of dopamine neurons has the potential to release dopamine and reconstruct neural networks

Stem cell-derived dopamine neurons are an individualized disease-modifying approach for restorative cell replacement therapy.


Aspen Neuroscience is the leading company using a patient’s own cells to develop cell replacement therapies.

Induced Pluripotent Stem Cells (iPSCs) are derived from somatic cells by transient expression of pluripotency-associated transcription factors (Yamanaka Patents).

iPSCs are functionally indistinguishable from embryonic stem cells derived from 5-day embryos.

aspenVenn 01

iPSCs have all the strengths of embryonic stem cells without the limitations of allogeneic therapy.

Comparison of Autologous and Allogeneic Therapy


We are scaling out manufacturing in preparation to provide a personalized cell therapy that avoids the need for immunosuppression.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.